Transarterial Radioembolization
Transarterial Radioembolization - Related Videos
08:55
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
0 Views •
Cited by 3 •
2016
Oncolytic virotherapies are under development as novel therapeutics for the treatment of hepatocellular carcinoma (HCC). Here we describe a method for locoregional therapy of HCC via hepatic arterial administration of oncolytic virus.
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
09:49
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
0 Views •
Cited by 22 •
2013
Dual-phase cone-beam computed tomography (DP-CBCT) is a useful intraprocedural imaging technique for transarterial chemo-embolization treatment with drug-eluting beads of hepatocellular carcinoma. DP-CBCT has been used to perform three major steps in oncologic interventional radiology: tumor localization (see), navigation and intraprocedural catheter guidance (reach), and intraprocedural evaluation of treatment success (treat).
FAQs
Treatment planning depends on three linked assessments: imaging identifies tumor distribution, vascular mapping shows how blood reaches the lesions, and dosimetry guides the intended radiation delivery. Patient selection adds a clinical filter, particularly when surgery or thermal ablation is unsuitable. Together, these steps help target tumors while limiting exposure to surrounding tissue and support decisions about whether TARE is appropriate.
The microspheres become lodged in vessels that feed the tumor, positioning the radioactive source close to malignant tissue. Microspheres containing yttrium-90 then emit beta radiation over time rather than delivering radiation broadly from outside the body. This combination of vascular placement and ongoing local emission concentrates treatment in the tumor region and helps limit radiation exposure to nearby tissue.
TARE directs treatment through the arterial blood supply of selected liver tumors, creating a locoregional approach rather than relying on a treatment aimed generally at the body. Because radiation is concentrated near tumor-feeding vessels and surrounding exposure is limited, the therapy may control tumor growth while helping preserve liver function in appropriately selected patients.
The procedure begins with imaging and vascular mapping to identify the relevant hepatic arterial anatomy and tumor-feeding vessels. Clinicians then catheterize the hepatic artery and inject the microspheres through that route. Dosimetry helps determine the planned radiation delivery, while the microspheres lodge in tumor-feeding vessels and release localized beta radiation over time.
Clinicians may consider TARE for selected patients with primary liver cancer or metastatic cancer involving the liver. It is particularly relevant when surgery or thermal ablation is unsuitable. The decision depends on imaging findings, vascular anatomy, dosimetry, liver-related considerations, and overall patient selection, rather than on tumor presence alone.
Potential outcomes include control of tumor growth, preservation of liver function, and support for treatment strategies that lead toward transplantation. TARE may also serve as a bridge to transplantation in selected patients. These outcomes depend on careful planning and patient selection, so treatment response and suitability must be considered within the broader clinical context.